Company: MIRM
Filing Date: 2025-12-19
Form Type: 8-K
Source: 0001193125-25-325825
Chunk: 0

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-12-19
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01      Entry into a Material Definitive Agreement.  

On December 18, 2025, Mirum Pharmaceuticals, Inc. (the “ Company”) entered into a subscription agreement (the “ Subscription Agreement”) with entities associated with TCG Crossover Management, LLC (“ TCGX”), an institutional investor (the “ PIPE Investors”), pursuant to which the PIPE Investors have agreed, subject to the terms and conditions of the Subscription Agreement, to purchase immediately following the Closing (as defined below), 1,000,000 shares (the “ PIPE Shares”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock”), for an aggregate gross purchase price of approximately $68,480,000 (the “ Private Placement”). The purchase price per PIPE Share is $68.48. As used herein, “ Closing” means the closing of the previously announced proposed mergers (the “ Mergers”) pursuant to the Agreement and Plan of Merger and Reorganization, dated December 6, 2025, by and among the Company, Bjork Merger Sub I, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company, Bjork Merger Sub II, LLC, a Delaware limited liability company and a direct wholly owned subsidiary of the Company, Bluejay Therapeutics, Inc., a Delaware corporation (“ Target”), and Fortis Advisors LLC, a Delaware limited liability company, solely in its capacity as the representative, agent and attorney in fact of the Target security holders. The Mergers are expected to close in the first quarter of 2026, subject to the satisfaction or waiver of customary closing conditions.

The Subscription Agreement contains customary representations and warranties of the Company, on the one hand, and the PIPE Investors, on the other hand, and certain conditions to closing, including customary conditions and the Closing of the Mergers. The securities described above to be issued and sold to the PIPE Investors pursuant to the Subscription Agreement will not be registered under the Securities Act of 1933, as amended (the “ Securities Act”), in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act.

Also on December 18, 2025, the Company entered into a registration rights agreement (the “ Registration Rights Agreement”) with the PIPE Investors pursuant to which the Company agreed to register for resale the PIPE Shares, which agreement will become effective upon the closing of the Private Placement. Under the terms of the Registration Rights Agreement, the Company